Nasdaq ikna.

Common Stock, $0.001 par value per share IKNA The Nasdaq Global Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule . 12b-2. of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☒Nov 18, 2023 · Ikena Oncology Inc (NASDAQ:IKNA) showed a performance of -46.11% in past 30-days. Number of shares sold short was 1.28 million shares which calculate 16.64 days to cover the short interests. Wall Street analysts have assigned a consensus price target of $8.33 to the stock, which implies a rise of 78.39% to its current value. Previous investments include Icosavax (NASDAQ: ICVX), Kymera Therapeutics (NASDAQ ... (NASDAQ: IKNA), Synthekine and Vanqua Bio. Previous to Omega Funds, Paulina ...BOSTON, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA), a targeted oncology company navigating new territory in patient-directed cancer treatment, today announced that three ...

American International Group Inc. bought a new position in Ikena Oncology, Inc. (NASDAQ:IKNA – Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 10,232 shares of the company’s stock, valued at approximately $67,000. Other hedge funds have also added to or […]

BOSTON, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment ...

Nov 24, 2023 · According to 4 analysts, the average rating for IKNA stock is "Strong Buy." The 12-month stock price forecast is $16.0, which is an increase of 288.35% from the latest price. Analyst Forecast According to 4 analysts, the average rating for IKNA stock is "Strong Buy." The 12-month stock price forecast is $14.25, which is an increase of …BOSTON, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA), a targeted oncology company navigating new territory in patient-directed cancer treatment, today announced that three ...Third Quarter 2022 Financial Results. As of September 30, 2022, Ikena had $174.4 million in cash, cash equivalents, and marketable securities, and believes this will be sufficient to meet its ...

BOSTON, May 15, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”, “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, announced today the pricing of an underwritten offering of 6,110,000 shares of common stock (the “Shares”) at an offering price of $6.55 per share.

Follow. BOSTON, April 28, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today ...

9 nov. 2023 ... Ikena Oncology, Inc (NASDAQ: IKNA) reported its quarterly financial results and presented preliminary data from the ongoing dose escalation ...Ikena Oncology, Inc. (IKNA) NasdaqGM - NasdaqGM Real Time Price. Currency in USD. Follow. 2W 10W 9M. 1.6700 +0.0900 (+5.70%) As of 10:38AM EST. Market open. 1d. SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and …BOSTON, Dec. 08, 2021 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company navigating new territory in patient-directed cancer treatment, today ...7 août 2023 ... ... Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, and Pionyr ...BOSTON, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company navigating new territory in patient-directed cancer treatment, today ...BOSTON, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today presented ...

Oct 5, 2022 · BOSTON, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced ... DSP Group, Inc. (NASDAQ:DSPG) is the most popular stock in this table. On the other hand Atomera Incorporated (NASDAQ: ATOM ) is the least popular one with only 5 bullish hedge fund positions.19 oct. 2022 ... (Nasdaq: IKNA, “Ikena”), una compañía de oncología específica que forja un nuevo territorio en el tratamiento del cáncer dirigido por el ...BOSTON, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment ...7 août 2023 ... (Nasdaq: IKNA, Ikena), a targeted oncology company forging new territory in patient-directed cancer treatment, and Pionyr Immunotherapeutics ...

Home IKNA • NASDAQ. Ikena Oncology Inc. Follow. Share. $3.61. Oct 19, 12:03:05 PM GMT-4 · USD · NASDAQ · Disclaimer. search Compare to. Lexicon Pharmaceuticals Inc.

According to the issued ratings of 4 analysts in the last year, the consensus rating for Ikena Oncology stock is Buy based on the current 4 buy ratings for IKNA. The average twelve-month price prediction for Ikena Oncology is $11.67 with a high price target of $13.00 and a low price target of $11.00. Learn more on IKNA's analyst rating history.BOSTON, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA), a targeted oncology company navigating new territory in patient-directed cancer treatment, today announced that three ...Every investor in Ikena Oncology, Inc. (NASDAQ:IKNA) should be aware of the most powerful shareholder groups. Insiders often own a large chunk of younger, smaller, companies while huge companies ...BOSTON, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced a next-generation mitogen-activated protein kinase (MEK)-RAF complex inhibitor, IK-595, has been nominated as the company’s first development ...BOSTON, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA), a targeted oncology company focused on developing novel cancer therapies targeting key signaling pathways, today ...Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) announced the first patient was dosed in a planned 52-week open label active treatment extension study of MAESTRO-NAFLD-1, a 52-week Phase 3 study of ...Ikena Oncology Inc (NASDAQ:IKNA) showed a performance of -46.11% in past 30-days. Number of shares sold short was 1.28 million shares which calculate 16.64 days to cover the short interests. Wall Street analysts have assigned a consensus price target of $8.33 to the stock, which implies a rise of 78.39% to its current value.Posted 8:51:03 PM. About IkenaIkena Oncology (NASDAQ: IKNA) is a clinical-stage, targeted oncology company that…See this and similar jobs on LinkedIn.Overview News Ikena Oncology Inc. No significant news for in the past two years. Key Stock Data P/E Ratio (TTM) N/A EPS (TTM) $-1.62 Market Cap 72.39 M Public Float N/A N/A …3 mai 2022 ... Maude Tessier joins Seismic after serving as Chief Business Officer of Ikena Oncology (Nasdaq: IKNA), a clinical-stage biotech company, where ...

BOSTON, Oct. 07, 2021 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company navigating new territory in patient-directed cancer treatment, today ...

He is a director and co-founder of IFM Therapeutics, Intellia Therapeutics (NASDAQ: NTLA) and Triplet Therapeutics. Jean-François also serves on the boards of Ikena Oncology (NASDAQ: IKNA) and Scorpion Therapeutics. Some of his prior investments include Arteaus Therapeutics (acquired by Eli Lilly), CoStim Pharmaceuticals (acquired by …

BOSTON, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company navigating new territory in patient-directed cancer treatment, today ...Nov 24, 2023 · Ikena Oncology (NASDAQ:IKNA) and Sangamo Therapeutics (NASDAQ:SGMO) are both small-cap medical companies, but which is the superior investment?We will contrast the two companies based on the strength of their media sentiment, analyst recommendations, dividends, community ranking, earnings, profitability, valuation, institutional ownership and risk. Check the Ikena Oncology, Inc. stock price today on the NASDAQ stock exchange and access historical IKNA stock price chart. Get the latest Ikena Oncology, ...Find the latest Institutional Holdings data for Ikena Oncology, Inc. Common Stock (IKNA) at Nasdaq.com.Formula One Group (NASDAQ:FWONA) has seen a decrease in hedge fund sentiment lately. Formula One Group (NASDAQ: FWONA ) was in 19 hedge funds' portfolios at the end of the first quarter of 2021 ...Find the latest Financials data for Ikena Oncology, Inc. Common Stock (IKNA) at Nasdaq.com.Ikena acquired all of Pionyr’s assets, including approximately $43 million in net cash, in exchange for shares of IKNA stock, in a combination of common stock and non-voting convertible ...Nov 17, 2023 · See the latest Ikena Oncology Inc stock price (IKNA:XNAS), related news, valuation, dividends and more to help you make your investing decisions. Nov 17, 2023 · See the latest Ikena Oncology Inc stock price (IKNA:XNAS), related news, valuation, dividends and more to help you make your investing decisions. Mar 17, 2022 · BOSTON, March 17, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena™”, “Company”), a targeted oncology company forging new territory in patient-directed cancer ...

Third Quarter 2022 Financial Results. As of September 30, 2022, Ikena had $174.4 million in cash, cash equivalents, and marketable securities, and believes this will be sufficient to meet its ...9 nov. 2023 ... (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced ...Ikena Oncology, Inc. (NASDAQ:IKNA) fell 12.3% to $1.43 in pre-market trading. Ikena Oncology recently reported worse-than-expected third-quarter revenue results.Instagram:https://instagram. auto insurance newsfidelity transfer stocks between accountspro dashboardent auto loan calculator IKNA technical analysis. This gauge displays a real-time technical analysis overview for your selected timeframe. The summary of Ikena Oncology, Inc. is based on the most popular …Nkarta, Inc. Common Stock (NKTX) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. best renters insurance bostonroot stock Prior to Seismic, she served as Chief Business Officer of Ikena Oncology (Nasdaq: IKNA), a clinical-stage biotech company, where she built and managed the business development, legal and corporate strategy functions. ... where he built the finance and accounting infrastructure in support of its transition to a Nasdaq-listed public company.To learn more about the company, technology solutions and career opportunities, visit us on LinkedIn, on Twitter @Nasdaq, or at www.nasdaq.com. Media Contact Emily Pan [email protected] +1 (646 ... best chart software BOSTON, March 17, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena™”, “Company”), a targeted oncology company forging new territory in patient-directed cancer ...Analyst Forecast According to 4 analysts, the average rating for IKNA stock is "Strong Buy." The 12-month stock price forecast is $14.25, which is an increase of …BOSTON, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA), a targeted oncology company navigating new territory in patient-directed cancer treatment, today announced that three ...